Introduction
The Ras proteins initiate multiple signaling pathways that affect cell growth, differentiation, and survival (Joneson and Bar-Sagi, 1997) . Ras activation requires the exchange of bound GDP for GTP, and in normal cells, this process is ligand-dependent. The ras genes are often mutated in human tumors, and such genes encode Ras proteins that are constitutively active and oncogenic (Adams and Cory, 1991; Bos, 1989) . Although transgenes encoding activated forms of Ras induce tumors when introduced into mice, they do so more effectively when presented to mice in combination with other transforming agents (Andres et al., 1988; Sandgren et al., 1989) . Moreover, ras transgenes and endogenous ras mutations are often found in precancerous lesions (Kumar et al., 1990; Suda et al., 1987) . These findings indicate that the spectrum of events induced by Ras is insufficient for full and efficacious neoplastic progression. In addition to events that promote cell proliferation and survival, this spectrum also includes events that inhibit these processes and that thus offset the oncogenic potential of activated Ras proteins (Frame and Balmain, 2000) .
The cyclin-dependent kinases (CDKs) orchestrate the passage of cells through the cell cycle (Johnson and Walker, 1999) . CDK activation requires cyclin association, and cyclin-CDK activity is negatively regulated by a group of proteins termed CDK inhibitors (CKIs). The CKI family includes p21 Cip1 and p27 Kip1 , both of which interact with and inhibit the activity of complexes containing the D cyclins and cdk4 or cdk6, cyclin E and cdk2, and cyclin A and cdk2 (Bagui et al., 2000; Sherr and Roberts, 1995) . When active, these complexes implement G0/G1 progression and S phase entry. In normal cells, the ratio of cyclins to CKIs is precisely controlled by signals originating in the extracellular environment and by feedback mechanisms that come into play as cells traverse the cell cycle. As a result, CDK activation is limited in extent and duration and to cell populations whose expansion is advantageous to the organism. The mechanisms controlling the levels of cyclins and/or CKIs are often dysregulated in tumor cells, where consequent increases in the cyclin/CKI ratio promote inappropriate cyclin-CDK activation and unchecked proliferation (Della Ragione et al., 1999) .
Studies investigating the anti-tumor potential of p21 Cip1 and p27 Kip1 have shown that p21 Cip1 -null mice do not develop tumors, at least at an early age, and that p27
Kip1 -null mice develop only benign pituitary adenomas (Brugarolas et al., 1995; Deng et al., 1995; Martin-Caballero et al., 2001; Nakayama et al., 1996) . However, loss of cell cycle inhibitors might expedite tumor formation induced by other agents. In a previous study, we tested this premise by generating p21
Cip1 -null mice that expressed an activated form of Ras (encoded by the v-Ha-ras transgene under control of the MMTV promoter) (Adnane et al., 2000) . We found that ras/21 7/7 mice developed tumors (primarily salivary and mammary) at earlier times and at higher multiplicities than did ras/p21 +/+ mice. Tumors grew at similar rates in both groups of mice, suggesting that p21
Cip1 suppresses the oncogenic actions of v-HaRas by inhibiting proliferation at a very early stage of tumorigenesis (i.e., before tumors are detectable) or by affecting processes other than cell cycle traverse. Such processes may include those involved in differentiation; the capacity of p21
Cip1 to modulate differentiation in a cell cycle-independent manner has been described (Di Cunto et al., 1998; Missero et al., 1996; Zezula et al., 2001) .
To further explore the relationship between genetic alterations and the loss of CKIs in tumorigenesis, we have performed two additional studies that build upon our previous results (Adnane et al., 2000) . The first study addresses the role of p21
Cip1 in tumor formation initiated by agents other than v-Ha-Ras. For these experiments, wild type and p21
Cip1
-null mice were treated with the DNA mutagen, urethane. Urethane has been shown to induce lung and liver tumors in mice by causing mutations in either the ras genes (tumor-sensitive mice) or other as yet unidentified genes (tumor-resistant mice, as used in the study described here) (Dragani et al., 1991; Mirvish, 1968; Nuzum et al., 1990; Wiseman et al., 1986) . The second study examines tumor formation in MMTV/v-Ha-ras mice lacking p27
Kip1 rather than p21
Cip1 . We chose p27 Kip1 as a potential substitute for p21
Cip1 because both CKIs target the same cyclin-CDK complexes and modulate differentiation by mechanisms unrelated to cell cycle regulation (Hauser et al., 1997; Quaroni et al., 2000; Sherr and Roberts, 1995) . Our data show that treatment of p21
Cip1 -null mice with urethane recapitulates the pattern of tumor formation seen in ras/p21 7/7 mice (Adnane et al., 2000) . We also find that v-Ha-Rasinduced tumorigenesis is potentiated by loss of p27 Kip1 , although in a manner distinct from that seen in ras/p21 7/7 mice.
Results

Tumor formation in p21
Cip1 -null mice exposed to urethane
In our previous study, we showed that loss of p21
Cip1 accelerated the onset of tumor formation and increased tumor multiplicity in mice expressing the v-Ha-ras transgene (Adnane et al., 2000) . To determine whether the absence of p21 Cip1 predisposes mice to other cancer-causing agents, p21 +/+ and p21 7/7 mice were injected with urethane or with saline, as vehicle control. Groups of mice were sacrificed at specified times and necropsies were performed. Inbred mouse strains differ in their sensitivities to spontaneous and carcinogen-induced tumor formation, and the mice used in our study (all from the same mixed C57BL/6 and 129 genetic background) were derived from tumorresistant parental strains (Malkinson and Beer, 1983; Smith et al., 1973) .
Saline-injected mice did not develop tumors of any type during the experimental period (9 months) regardless of whether p21
Cip1 was expressed (data not shown). This finding is in agreement with a previous study showing that p21
Cip1 -null mice are tumor-free for at least 1 year after birth (Brugarolas et al., 1998) . Tumors were present in urethane-treated mice, and the vast majority of these tumors were in the lungs. The number of urethane-injected mice with macroscopically observable lung tumors was noted for each time point. Five out of nine p21 7/7 mice contained readily detectable tumors at 2 months after injection, whereas none of the p21 +/+ mice were tumor-positive at this time (zero out of seven) ( Figure 1a , Table 1 ). After 2 months, the number of p21 7/7 mice with tumors increased further, with 100% of the mice developing tumors by 6 -9 months. Beginning at 3.5 months, tumors were also apparent in the p21 +/+ mice; however, at 3.5, 5 and 6 months after urethane injection, the percentage of tumor-bearing mice was substantially lower in the p21 +/+ cohort than in the p21 7/7 cohort. For example, at 3.5 months, 50% (six out of 12) of the p21 7/7 mice had tumors as compared with 10% (one out of 10) of the p21 +/+ mice. By 9 months, however, the number of p21 +/+ mice with tumors (15 out of 16) approached that of p21 7/7 mice (10 out of 10). Consistent with earlier tumor onset, the tumors in p21
Cip1 null mice were larger than those in wild type mice at later time points, as judged by visual inspection. These data show that although almost all of the urethane-treated mice eventually developed tumors, mice lacking p21
Cip1 became tumor-positive at earlier times than did mice expressing p21
Cip1 . In this respect, urethane-treated p21 7/7 mice precisely mimicked ras/ p21 7/7 mice (Adnane et al., 2000) .
We also determined the average number of lung tumors in tumor-positive mice and found that at 3.5, 6 and 7 months after urethane injection, p21 7/7 mice contained approximately twice as many tumors as did p21 +/+ mice (Table 1) . For example, at 6 months, average tumor multiplicities were 3.0 and 5.8 for p21
+/+ and p21 7/7 mice, respectively. Moreover, examination of all of the tumor numbers shows that five p21 7/7 mice contained 10 or more tumors, with one mouse developing 31 tumors, another developing 23 tumors, and a third displaying tumor consolidation of an entire lobe. In contrast, only one p21 +/+ mouse had more than 10 tumors (11 tumors at 9 months) (Figure 1b) . These findings suggest that loss of p21 Cip1 increases tumor multiplicity in urethane-treated animals, and the average twofold increase in tumor multiplicity seen in p21 7/7 as compared with p21 +/+ mice is similar to that seen previously in ras/p21
versus ras/p21 +/+ mice (Adnane et al., 2000) . Although average tumor multiplicities were comparable in p21 +/+ and p21 7/7 mice at 9 months after urethane injection, it is clear from the data presented that loss of p21 Cip1 increases the rate at which multiple tumors are formed.
Because tumors at earlier time points are small and thus difficult to detect macroscopically, we performed a detailed microscopic examination of the lungs of mice sacrificed at 2 months after injection. Both lobes were serially sectioned in their entirety, stained with H & E, and inspected microscopically for the presence of tumors. No lung tumors were seen in mice injected with saline or in p21 +/+ mice exposed to urethane (Figure 2a ). On the other hand, 90% (eight out of nine) of the urethane-injected p21 7/7 mice contained microscopically detectable tumors which were classified as bronchioloalveolar adenomas. Moreover, three of these mice had more than one tumor (Figure 2b) . Thus, by means of a systematic microscopic evaluation, we were able to show that urethane-treated p21 +/+ mice at 2 months were essentially lung tumor-free, whereas urethane-treated p21 7/7 mice contained lung tumors in addition to those observed macroscopically. These findings provide further evidence of increased tumor incidence in mice exposed to urethane in the absence as compared with the presence of p21
Cip1 . Detailed histologic examinations were performed on the lungs of twenty p21 +/+ and nineteen p21 7/7 mice sacrificed 6, 7 and 9 months after urethane administration. All mice developed bronchioloalveolar adenomas, and a typical adenoma is pictured in Figure  3a . This tumor contains few, if any, mitotic figures and is comprised of type II pneumocytes in a tubulopapillary pattern of growth with a well-demarcated margin. The tumor cells in the adenoma contain abundant Figure 1 Tumor formation in p21 +/+ and p21 7/7 mice exposed to urethane. Mice were injected intraperitoneally with urethane (1000 mg/kg of body weight) at 6 weeks of age. Cohorts of mice were sacrificed at the indicated times, and the lungs of each mouse were inspected visually for the presence of tumors. (a) The number of mice with lung tumors at each time point was determined. Statistically significant differences (P-value less than 0.1) between p21 +/+ and p21 7/7 mice are indicated by an asterisk (*). Significant P-values are as follows: 0.0014 (2 months), 0.03 (3.5 months) and 0.07 (6 months). Although the percentages of p21 +/+ and p21 7/7 mice with lung tumors at 5 months were 27 and 70%, respectively, the P-value (0.15) is not significant, possibly due to the low number of animals sacrificed at 5 months. (b) The number of lung tumors per mouse was determined a Percentage of total mice that contained lung tumors at the specified time point. b Average number of lung tumors per tumor-positive mouse at the specified time point. For experimental details, see the legend to Figure 1 eosinophilic cytoplasm and round, monomorphic nuclei. Three out of 20 p21 7/7 mice developed bronchioloalveolar carcinomas beginning 6 months after urethane injection, and an example of a carcinoma is shown in Figure 3b . This heterogeneous tumor has infiltrative, poorly demarcated margins, Figure 2 Microscopic examination of the lungs 2 months after injection of p21 +/+ and p21 7/7 mice with urethane. Mice were injected intraperitoneally with saline or urethane (1000 mg/kg of body weight) at 6 weeks of age. Seven p21 +/+ and nine p21 7/7 mice were sacrificed at 2 months after injection. Both lobes of the lungs of each mouse were sectioned, stained with H&E, and examined microscopically for the presence of tumors. (a) The percentage of mice with lung tumors was determined.
(b) The number of lung tumors per urethane-treated mouse was determined Figure 3 Histologic appearance of lung and liver tumors in urethane-treated p21 7/7 mice. A bronchioloalveolar adenoma (a) and a bronchioloalveolar carcinoma (b), both from p21 7/7 mice sacrificed at 6 months after treatment with urethane, are shown. Note the well-demarcated margin (a, star) and the lack of mitotic figures in the adenoma compared with the infiltrative margin (b, star) and numerous mitotic figures (b, arrows) of the carcinoma. Also shown are a hemangioma (c) and a hemangiosarcoma (d), both from the livers of p21 7/7 mice sacrificed at 9 months after urethane treatment. Note the capillaries lined by well-differentiated endothelial cells (c, arrows) and the lack of mitotic figures in the hemangioma compared with the highly atypical endothelial cells with multiple nucleoli (d, arrows) in the hemangiosarcoma. All tumors were stained with H & E and are at 6400 magnification many mitotic cells, and large pleomorphic tumor cells, often with vacuolated cytoplasm (Figure 3b ). The nuclei in these cells are large and irregular in shape, and the nuclear to cytoplasmic ratio is increased relative to that seen in the cells in the adenoma. Bronchioloalveolar carcinomas were not seen in urethane-treated p21 +/+ mice (zero out of 19) at any time during the study period. These findings suggest that loss of p21
Cip1 promotes the conversion of benign adenomas to malignant carcinomas.
Although much less common than lung tumors, liver hemangiomas were also present in urethane-treated p21 +/+ and p21 7/7 mice at later time points. Hepatic hemangiomas were focal and composed of small capillaries lined by well-differentiated endothelial cells present between hepatocyte cords (Figure 3c ). Hepatic angiosarcomas were found only in urethane-treated p21 7/7 mice and consisted of vascular channels lined with highly atypical endothelial with a dense fibrous stroma (Figure 3d ). The angiosarcomas contained numerous mitotic cells and areas of necrosis. The nuclei of the tumor cells in the angiosarcoma were large and irregular in shape and had prominent nucleoli. A splenic lymphoma, a thymic lymphoma, a uterine leiomyosarcoma, and an ovarian luteoma were also detected in urethane-treated p21 7/7 mice. Another abnormality common to both groups of mice was splenomegaly, which was seen in 13.5% (eight out of 59) of the p21 +/+ mice and 8% (five out of 61) of the p21 7/7 mice.
Tumor formation in p27
Kip1
-null mice expressing v-Ha-Ras
To determine whether loss of p27 Kip1 recapitulates loss of p21
Cip1 in the MMTV/v-Ha-ras mouse model, we generated p27
Kip1 wild type, heterozygous, and nullizygous mice, all expressing the MMTV/v-Ha-ras transgene. Rather than sacrificing groups of mice and performing necropsies (as was done in the urethane studies), we examined live MMTV/v-Ha-ras mice for tumor formation by observation and palpation, as was done in our previous study of ras/p21 7/7 mice (Adnane et al., 2000) . Mice were examined every week beginning 1 month after birth and were only sacrificed when tumor size reached 2 cm. Previous studies have shown that MMTV/v-Ha-ras mice spontaneously develop salivary and mammary adenocarcinomas and benign Harderian gland hyperplasias, all of which are easily detected externally (Sinn et al., 1987) . Urethaneinduced lung tumors, on the other hand, can only be detected internally and thus only by sacrifice and necropsy.
The times at which ras/p27 +/+ , ras/p27 +/7 , and ras/ p27 7/7 mice developed salivary, mammary, and Harderian gland tumors are shown in Figure 4a ,b,c, respectively. T 50 values (the times at which 50% of the mice in each group became tumor-positive) are also presented. Most mice in all three groups developed mammary tumors, whereas salivary and, in particular, Harderian gland tumors were less frequent. Regardless of tumor type, T 50 values for ras/p27 +/+ , ras/p27 +/7 , and ras/p27 7/7 mice were not statistically different (Figure 4a,b,c) . Tumor multiplicities (as determined for mammary and salivary tumors) were also similar in the three groups of mice (Figure 4d and data not shown). For example, the average numbers of mammary tumors per tumor-positive mouse at the time of sacrifice were 4.1 (ras/p27 +/+ ), 4.2 (ras/p27 +/7 ), and 4.0 (ras/p27 7/7 ) (Figure 4d ). Thus, unlike p21
Cip1 (Adnane et al., 2000) , p27 Kip1 does not affect either the timing or frequency of tumor formation in mice expressing the MMTV/v-Ha-ras transgene.
Tumor volumes were monitored weekly in ras/p27
+/7 , and ras/p27 7/7 mice, and growth rates were calculated. Both salivary tumors and, to a lesser extent, mammary tumors grew faster in ras/p27 7/7 mice than in ras/p27 +/+ mice ( Figure 5 ). Growth rates for salivary tumors in ras/p27 +/+ and ras/p27 7/7 mice were 0.247 and 0.811 cm 3 per week, respectively (P=0.0001), and growth rates for mammary tumors in ras/p27 +/+ and ras/p27 7/7 mice were 0.403 and 0.546 cm 3 per week, respectively (P=0.016) ( Figure  5a ). Salivary tumors grew at similar rates in ras/p27 +/7 and ras/p27 7/7 mice, whereas mammary tumors grew at similar rates in ras/p27 +/7 and ras/p27 +/+ mice (data not shown). Harderian tumors were too small to be measured accurately. As an alternative way of assessing tumor growth rate, we plotted the times at which the size of mammary and salivary tumors reached 2 cm in any dimension; in accordance with NIH guidelines, mice were sacrificed at this time. As listed in Figure 5b , T 50 values were 228, 194 and 146 days for ras/p27 +/+ , ras/p27 +/7 , and ras/p27 7/7 mice, respectively. The differences between the T 50 values for ras/p27 7/7 and ras/p27 +/+ mice were statistically significant (P=0.09), as were those for ras/p27 7/7 and ras/p27 +/7 mice (P=0.07). Collectively, the data in Figure 5 show that loss of p27
Kip1 increases tumor growth rate in MMTV/v-Haras mice. In this respect, p27
Kip1 differs from p21 Cip1 , which had no effect on tumor growth rate in these mice (Adnane et al., 2000) .
Regardless of p27 Kip1 dosage, Ras-induced tumors contained a similar (and very low) percentage of apoptotic cells (as determined by TUNEL analysis) as did normal tissues (data not shown). This finding suggests that loss of p27 Kip1 enhances tumor growth by increasing the percentage of cycling cells (rather than the percentage of surviving cells) in the tumors, and this was confirmed by histologic examination. Fixed sections of salivary and mammary tumors were incubated with antibody to Ki-67, a marker of cell proliferation, and immunostaining was performed. As shown in Figure 6a , the percentage of Ki-67-positive nuclei in ras/p27 +/+ tumors ranged from 0 to 30%. On the other hand, the percentage of Ki-67-positive nuclei in ras/p27 7/7 tumors ranged from 0 to 70%, and almost 50% of these tumors contained more than 30% stained nuclei. Figure 6b shows a typical slow-growing ras/p27 +/+ tumor in which stained nuclei and mitotic figures are rare (top panels), as well as a particularly aggressive ras/p27 7/7 tumor with numerous stained nuclei and mitotic figures (bottom panels). ras/p27 +/7 tumors displayed an intermediate level of staining that was not significantly different from ras/p27 +/+ or ras/ p27 7/7 tumors ( Figure 6a ). However, when the three groups were compared together, the P-value was 0.097, which is suggestive of an overall inverse correlation between p27
Kip1 dosage and percent stained nuclei. These findings suggest that p27
Kip1 suppresses v-HaRas-induced tumorigenesis by reducing the proliferative capacity of tumor cells and, consequently, the size of the tumors.
As noted above, many of the ras/p27 7/7 tumors displayed features characteristic of highly aggressive tumors, and additional examples of such features are illustrated in Figure 7 . In Figure 7a , a dilated and hyperplastic mammary duct is seen adjacent to an invasive mammary carcinoma. Figure 7b shows a wellcircumscribed salivary gland myoepithelioma characterized by a proliferation of spindle-shaped cells (myoepithelial cells) admixed with epithelioid cells (squamoid cells). In addition to the mammary, salivary, and Harderian glands, other organs and tissues were also examined for tumors. Five ras/p27 +/+ , five ras/p27 +/7 , and six ras/p27 7/7 mice were chosen at random for a detailed histologic analysis, and the percentages of lung and spleen tumors in these mice were 20, 80 and 50%, respectively (data not shown). No colon, kidney, or liver tumors were observed in any of these mice.
Discussion
The results of this study, coupled with those of our previous study (Adnane et al., 2000) , show that loss of p21
Cip1 enhances the formation of lung tumors in urethane-treated mice and mammary and salivary tumors in mice expressing the MMTV/v-Ha-ras transgene. In both systems, removal of p21 Cip1 accelerated tumor onset, both in terms of number of mice with tumors and number of tumors per tumorpositive mouse. Thus, p21
Cip1 apparently modulates early aspects of both urethane-and v-Ha-Ras-induced tumorigenesis. In urethane-treated mice, p21
Cip1 may also affect later events. In addition to lung adenomas, which were present in both p21 +/+ and p21 7/7 mice, sporadic lung carcinomas were seen in p21 7/7 mice starting at 6 months after urethane injection. We also show that the tumor phenotype of ras/p27 7/7 mice differs from that of ras/p21 7/7 mice. Unlike ras/p21
mice, ras/p27 7/7 mice did not develop tumors at earlier times or at higher multiplicities than did their wild type counterparts. Conversely, loss of p27 , and ras/p27 7/7 mice, n=17, 23 and 10, respectively. (d) The number of tumors of any type per mouse was determined weekly by observation and palpation. The numbers represent the final number of tumors per mouse prior to sacrifice. Mice were sacrificed throughout the experimental period whenever tumor size reached 2 cm or signs of morbidity were detected increased tumor growth rate whereas loss of p21 Cip1 did not. The effects of p27 Kip1 loss on tumor growth rate were most apparent for salivary tumors, although a small, statistically significant increase in the growth rate of mammary tumors was also observed. Deletion of p27
Kip1 appeared to promote tumor growth by increasing the percentage of cycling cells in the tumor. These findings suggest that p27
Kip1 and p21
Cip1 suppress tumorigenesis by different mechanisms and that the anti-tumor actions of p27 Kip1 reflect its capacity to inhibit CDK activation and consequent cell cycle traverse.
With some exceptions (Paramio et al., 2001; Weinberg et al., 1997) , previous studies support an anti-tumor function of p21
Cip1 . However, disagreement exists regarding the effects of p21
Cip1 loss on tumor formation. Similar to our findings, Topley et al. (1999) showed that p21 7/7 mice developed skin carcinomas earlier and at higher multiplicities than did wild type mice when co-treated with the chemical carcinogen, DMBA, and the tumor promoter, PMA. In the same system, Philipp et al. (1999) found that p21
Cip1 loss promoted the de-differentiation of squamous carcinomas but had no effect on tumor size or number. In mice expressing a mutant allele of the APC tumor suppressor gene, the absence of p21
Cip1 increased the incidence, multiplicity, and size of colon tumors (Yang et al., 2001) . On the other hand, deletion of one copy (although not both copies) of the p21 Cip1 gene increased the size but not the incidence of mammary tumors in mice expressing the Wnt-1 oncoprotein (Jones et al., 1999) . Obviously, additional studies are required to clearly define the function of p21
Cip1 in tumor suppression. Previous studies also support an anti-tumor function of p27 Kip1 . Fero et al. (1998) demonstrated increased tumor incidence and increased tumor-related mortality in p27
Kip1 null mice (as compared with wild type mice) exposed to g-irradiation or N-ethyl-N-nitrosourea. p21 Cip1 and p27 Kip1 target the same cyclin-CDK complexes, and cell cycle-independent effects of both CKIs on differentiation have been described (di Cunto , and ras/p27 7/7 mice. (a) After the first observation of a salivary (left panel) or mammary (right panel) tumor, tumor size was monitored weekly thereafter in ras/p27 +/+ and ras/p27 7/7 mice. Week 1 represents the first time that a particular tumor was seen, and size measurements were begun. Tumor diameters were measured in three dimensions using calipers, and tumor volumes were calculated. For salivary tumors, n=8 and 3 for ras/p27 +/+ and ras/ p27 7/7 mice, respectively. For mammary tumors, n=9 and 5 for ras/p27 +/+ and ras/p27 7/7 mice, respectively. (b) ras/p27 +/+ , ras/p27
, and ras/p27 7/7 mice were euthanized when the size of any type of tumor reached 2 cm. T 50 values represent the times (in days) when 50% of the mice in each group were sacrificed. P-values are as follows: ras/p27 +/+ versus ras/p27
, 0.96; ras/ p27 +/+ versus ras/p27
, 0.09; and ras/p27 +/7 versus ras/p27
, 0.07. Comparison of all three groups gives a P-value of 0.13 Figure 6 Proliferative index in tumors of ras/p27
, ras/p27
, and ras/p27 7/7 mice. (a) Salivary and mammary tumors were isolated from ras/p27 +/+ , ras/p27
, and ras/p27 7/7 mice sacrificed at various times when tumors measured 2 cm or when mice showed signs of morbidity. Formalin-fixed tumor sections were incubated with antibody to Ki-67 and immunostained as described in Materials and methods. The percentage of stained nuclei was determined. (b) At the time of sacrifice, a mammary carcinoma from a ras/p27 +/+ mouse (7.6 months of age) and a mammary carcinoma from a ras/p27 7/7 mouse (7.2 months of age) were fixed, sectioned, and either stained with H & E or incubated with antibody to Ki-67 and immunostained. Mitotic figures in the ras/p27 Hauser et al., 1997; Missero et al., 1996; Quaroni et al., 2000; Sherr and Roberts, 1995; Zezula et al., 2001) . For example, Zezula et al. (2001) showed that loss of p21
Cip1 delayed the differentiation of serum-starved oligodendrocyte precursor cells without affecting their capacity to growth arrest. Similarly, we found that p27
Kip1 antisense oligonucleotides blocked the suspension-induced differentiation of keratinocytes in the absence of cyclin-CDK activation and cell cycle reentry (Hauser et al., 1997) . Despite similarities in the actions of p21
Cip1 and p27 Kip1 , p21
Cip1
-null mice and p27
Kip1 -null mice are phenotypically distinct (Deng et al., 1995; Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996) . Most notably, p27
Kip1 mice are larger than their wild type littermates whereas p21 Cip1 mice are of normal size. p27 Kip1 and p21
Cip1 are also differentially expressed. For example, p27
Kip1 levels are high in mitogen-deprived cells and low in cycling cells whereas the reverse is true for p21
Cip1 (Agrawal et al., 1996; Firpo et al., 1994) . Because p27 Kip1 and p21 Cip1 behave similarly in some but not all respects, it is possible that these CKIs modulate tumorigenesis by different mechanisms. Our data show clear differences between the actions of p27
Kip1 and p21 Cip1 in the context of v-Ha-Ras-induced tumorigenesis and thus support this premise (data shown here and Adnane et al., 2000) . Interestingly, Ras activation increases p21
Cip1 levels and, perhaps in conjunction with other factors, reduces p27
Kip1 levels (Aktas et al., 1997; Serrano et al., 1997; Takuwa and Takuwa, 1997; Winston et al., 1996) . ras/p27 7/7 tumors contained a higher percentage of cycling cells than did ras/p27 +/+ tumors, whereas the percentages of cycling cells in tumors of ras/p21 +/+ and ras/p21 7/7 mice were comparable (data shown here and Adnane et al., 2000) . These observations suggest that p27
Kip1 antagonizes Ras-induced tumor formation via its capacity to function as a cell cycle inhibitor. p21
Cip1 may also suppress Ras-induced tumorigenesis by inhibiting cell cycle traverse; however, this inhibition would be restricted to the very early stages of tumorigenesis, where tumors are not yet detectable. Alternatively, p21
Cip1 may affect processes unrelated to cell proliferation, as proposed by Missero et al. (1996) . In this study, nude mice were injected subcutaneously with keratinocytes expressing v-Ha-Ras in the absence of either p27
Kip1 or p21 Cip1 . (No (or very small) lesions were detected in mice receiving ras/ 7/7 keratinocytes whereas aggressive squamous carcinomas were found in mice exposed to ras/p21 7/7 keratinocytes. Based on an analysis of the proliferative status and differentiation capacity of the two sets of keratinocytes, Missero et al. (1996) concluded that p21
Cip1 counteracts the transforming potential of Ras by promoting terminal differentiation, an event that is not duplicated by p27
Kip1 . Although p27
Kip1 and p21 Cip1 gene mutations are rare in human cancers (Ponce-Castaneda et al., 1995; Shiohara et al., 1997) , other events appear to limit the expression or actions of these CKIs during the tumorigenic process. For p21
Cip1 , such events include p53 gene mutations and Her-2/neu gene amplification, both of which are found frequently in human cancers (Slamon et al., 1987; Vogelstein and Kinzler, 1992; Zhou et al., 2001) . Reduced levels of p21
Cip1 have been seen in human colorectal cancers and are indicative of low survival rates (Zirbes et al., 2000) . Diminished expression of p27
Kip1 also correlates with poor prognosis, and increases in the degradation rate of p27
Kip1 have been detected in both lung and colorectal tumors (Catzavelos et al., 1997; Kawana et al., 1998; Loda et al., 1997; Porter et al., 1997) . Thus, in at least some human tumors, p27
Kip1 and p21 Cip1 are inefficiently expressed or functionally inactivated. As suggested by our studies on mouse models, such changes may expedite the development of human cancers in conjunction with other genetic alterations.
Materials and methods
Mice p21
Cip1 -null (p21 7/7 ) mice (from Dr Tyler Jacks) (Brugarolas et al., 1995) and p21
Cip1 -wild type (p21 +/+ ) mice (The Jackson Laboratory), both from the same mixed C57BL/6 and 129 genetic background, were used in the urethane study. For the Ras study, MMTV/v-Ha-ras transgenic mice in an inbred FVB/N genetic background (Charles River Laboratories) (Sinn et al., 1987) were crossed with p27
Kip1
-null (p27 7/7 ) mice from a mixed C57BL/6J and 129 genetic background (from Dr James Roberts) (Fero et al., 1996) to obtain MMTV/v-Ha-ras6p27 +/7 breeders. Since MMTV/vHa-ras male mice and p27
Kip1 -null females are sterile, MMTV/v-Ha-ras female mice were crossed with p27
Kip1 -null male mice to produce the study mice (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996; Sinn et al., 1987) . Littermate F2 generation p27
, and p27 7/7 mice containing the v-Ha-ras transgene (ras/p27 +/+ , ras/ p27 +/7 , and ras/p27 7/7 mice, respectively) were used in the experiments described. Interestingly, ras/p27 7/7 female mice were fertile, and ras/p27 +/+ , ras/p27 +/7 and ras/p27 7/7 female mice (unlike the parental MMTV/v-Ha-ras female mice) were capable of nursing their young.
Mouse genotyping
The p21 Cip1 , p27 Kip1 , and MMTV/v-Ha-ras genotypes were analysed by the polymerase chain reaction (PCR). Genomic DNA (gDNA) was isolated from an approximately 1 cm section of mouse tail using the DNeasy Tissue Kit (Qiagen) or the method of Davis et al. (1980) . For p21
Cip1 genotyping, the following PCR primers were used: p21 common, AAGCCTTGATTCTGATGTGG; p21 WT (generates wild type fragment=900 bp), TGACGAAGTCAAAGTTCCAC; and p21 Mu (generates mutant fragment=750 bp), GCTAT-CAGGACATAGCGTTG. The PCR reaction mixture contained sample gDNA, 1 mM of each primer, 10 mM TrisHCl (pH 8.3), 3.5 mM MgCl 2 , 75 mM KCl, 0.2 mM dNTP mix, 5% DMSO, and 2.5 U of Taq polymerase (Qiagen). Cycling parameters were as follows: incubation at 958C for 3 min, followed by 35 cycles at 948C for 1 min, 508C for 1 min, and 728C for 2 min, and ending with primer extension at 728C for 7 min.
For v-Ha-ras and p27
Kip1
genotyping, gDNA was amplified in the presence of 1.5 mM MgCl 2 , 0.2 mM dNTP mix, 16Qiagen buffer, 1 mM of each primer, and 2 U of Taq polymerase (Qiagen). The primer sequences for v-Ha-ras were: R-MMTV/v-Ha-ras (GGGCATAAGCACAGATAA-AACACT) and F-MMTV/v-Ha-ras (CCCAAGGCTTAAG-TAAGTTTTTGG), which generate a fragment of 852 bp after incubation. PCR parameters were as follows: 958C for 3 min, followed by 30 cycles of 958C for 1 min, 558C for 45 s, and 728C for 45 s, and ending with primer extension at 728C for 10 min. For p27 Kip1 , the primer sequences were: p27-K3 (common) TGGAACCCTGTGCCATCTCTAT; p27 F-N (generates mutant fragment=800 bp) CCTTCTATGGCC-TTCTTGACG; and p27-K5 (generates wild type fragment=900 bp) GAGCAGACGCCCAAGAAGC. Cycling parameters were as follows: incubation at 958C for 3 min followed by 40 cycles of 958C for 1 min, 618C for 45 s, and 728C for 45 s, and ending with primer extension at 728C for 7 min (Adnane et al., 2000) .
Treatment, monitoring, and sample collection
For the urethane study, 61 p21 7/7 mice and 59 p21 +/+ mice were injected intraperitoneally at 6 weeks of age with urethane (Sigma, 1000 mg/kg of body weight) dissolved in 0.9% NaCl or with 0.9% NaCl alone. Mice were monitored weekly for overall condition, and cohorts of mice from each group were sacrificed periodically. At the time of sacrifice, necropsies were performed as follows: the lungs, liver, kidneys, colon, and spleen were examined macroscopically for the presence of tumors, and lesions were described and counted. These organs and any other organs or tissues that appeared abnormal were fixed in 10% neutral buffered formalin for histopathological analysis.
For the Ras/p27 Kip1 project, monitoring and sample collection were performed as described previously (Adnane et al., 2000) . Briefly, 50 female offspring from the F2 generation (17 ras/p27 +/+ , 23 ras/p27 +/7
, and 10 ras/p27 7/7 mice) were inspected weekly for tumors by observation and palpation. Calipers were used to measure tumor diameters in three dimensions, and tumor volumes were calculated. Animals were sacrificed when tumors reached 2 cm in diameter or when morbidity was noted, and necropsies were performed. Particular emphasis was placed on an examination of the salivary, mammary, and Harderian (lacrimal) glands, the predominant sites of tumor formation in MMTV-v-Ha-ras mice (Sinn et al., 1987) . The lungs, liver, kidneys, spleen, and colon were also examined for the presence of lesions. Representative samples of normal and tumor tissue were fixed in 10% neutral buffered formalin for histologic evaluation.
All surgical and experimental procedures performed on mice were in accordance with the guidelines for the University of South Florida and the guidelines for the National Institutes of Health as outlined in 'Guide for Care and Use of Laboratory Animals' (NIH publication 85 -23).
Histology
For general microscopy, fixed tissues were embedded in paraffin blocks, 3 mm-thick sections were cut, and slides were stained with hematoxylin and eosin (H & E) (Richard-Allan Scientific) using standard histologic techniques. For determination of the proliferative status of Ras-induced tumors, tumor sections were incubated with an antibody to Ki-67 clone B56 (#36521A, Pharmingen) at a 1 : 400 dilution following microwave antigen retrieval with citrate buffer on an autostainer (Dako) using the LSAB+ kit (Dako). The percentage of apoptotic cells in the same tumor sections was determined by terminal deoxynucleotidyl transferasemediated dUTP nick end labeling (TUNEL) using the In Situ Cell Death Detection Kit (Boehringer-Mannheim).
Statistical analysis
For the urethane study, P values were based on the two-sided Fisher's Exact Test. The Mantel-Haenszel method was used for the stratified results to pool the contingency tables over all of the data. The Wilcoxon Rank Sum Test was used to compare the number of foci in the urethane-treated p21 +/+ and p21 7/7 mice. For the Ras/p27 Kip1 study, tumor frequencies in the three groups of mice (ras/p27 +/+ , ras/ p27 +/7 , and ras/p27 7/7 ) were compared using Fisher's Exact Test. For quantitative variables, comparisons were made using the Kruskal-Wallis Test for more than two groups, followed by Wilcoxon Rank Sum Tests for pairs of groups. The Kruskal-Wallis Test and the Wilcoxon Rank Sum Test are the non-parametric analogs of the one-way ANOVA and the pooled t-test, respectively, and are more appropriate when sample sizes are small and normality uncertain. Comparisons of the survival curves for independent groups were done using the Log Rank Test. All P-values are two-sided. Analyses were performed using Proc Freq, Proc Npar1way, Proc Lifetest, and Proc Lifetest of SAS (version 8).
